https://www.selleckchem.com/pr....oducts/paquinimod.ht
Results Between 2007 and 2016, we identified 6220 patients with BrM receiving non-stereotactic, brain-directed radiation. Only 2.20% of patients (n = 137) received memantine with radiation. Rates were 1.10% versus 5.14% in the period preceding (2007-2013) and following (2014-2016) the publication of RTOG 0614, respectively. Overall utilization of memantine remained low across several clinical, demographic, and prognostic variables. Conclusion Despite phase 3 evidence supporting memantine utilization among patients receiving WBRT, our
Like
Comment
Share
